Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 20, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
January 05, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102

Selective activation and expansion of Wilms’ Tumor 1 (WT1)-specific cytotoxic CD8+ T cells in preclinical models supports the potential for clinical activity treating WT1-expressing cancersFurther...
December 15, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
December 06, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
November 22, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
November 12, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Monotherapy data further enhances confidence in CUE-101 potential as single agent therapeutic in the refractory/metastatic human papillomavirus positive head and neck squamous cell carcinoma (HPV+...
November 10, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
October 21, 2021 12:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
October 04, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting

CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
September 28, 2021 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

Research demonstrates that platform technologies generate therapeutic molecules for selective delivery of immune activating signals, such as IL-2, to disease-relevant T cells, hence avoiding systemic...